TGFB1 and systemic sclerosis: In addition, our in vitro results indicate that treatment with serum from SSc patients is able to induce Ly-EndMT in HdLy-MVECs in a similar extent to TGFβ1, thus further supporting the notion that this mesenchymal transdifferentiation process may be effective in SSc.